Premier Biomedical Inc (BIEI)

[stervc]

Huge with this BIEI New COVID-19 Patent News...

BIEI, through Dr. Mitchell S. Felder, already have 18 patents issued. This means that he has 18 patents that were approved already by the federal government as I had explained that and much more within the post below:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=154958045

This means that the federal government already have a certain rapport and level of trust with Dr. Mitchell S. Felder because of his achievements. What some might not know is that there is a process that is involved before a Provisional Patent Application is even allowed to be filed. The federal database is researched first to make sure no other claim to such patent even exists. Since the application has been allowed to be filed... such rights strongly appears to be belonging to BIEI through Dr. Mitchell S. Felder. It also allows the term "patent pending" to be applied in connection with the description of the invention as confirmed from the link below:
https://www.uspto.gov/patents-getting-started/patent-basics/types-patent-applications/provisional-application-patent

This means that there is a very strong and likely chance that it will go from "patent pending" to becoming an "issued patent" which would bode well to be awesome for BIEI.

With this entire process of the patent submission and now being in "patent pending" status, nobody else could file for this patent as BIEI, through Dr. Felder, would own this technology. They have beaten all to the punch for ownership of this very important medical patent. This means that all others within the US (and globally) will have to do licensing and distribution agreements with BIEI to be able to use this technology as this includes "Big Pharma" too. Those using this technology/procedure without such licensing and distribution agreements with BIEI will be subjected to patent infringement violations which would financially bode well for BIEI. I can't say it enough that this is huge news for BIEI.

This is what will also be the trump card that could lead to "Big Pharma" wanting to get on board with BIEI to further enhance the development of the technology/medicines.

For those that are new to BIEI, Dr. Mitchell S. Felder is the Co-Founder, Chairman of the Board of Directors, Chairman of the Scientific Advisory Board, and a prolific inventor for BIEI. He is very qualified.

The volume has been primarily selling that's not coming from the company... hint hint. In my opinion, the company had to finally take the stand to get their shareholders back on board and to gain market sentiment from the previous death spiral that existed. This is key for positioning the company for sustained market growth in the near and distant future. I truly believe the CEO, William (Bill) Hartman, when he stated no reverse split and that no more shares are going to be issued that previously killed shareholders. I believe we are witnessing a new beginning. Eventually, those who are selling are going to run out of shares as BIEI will continue to grow. The "Supply vs Demand" principles are slowly turning around to be in our favor as shareholders.

Again, this is huge news for BIEI that I think all should read and read again:

https://www.otcmarkets.com/stock/BIEI/news/Premier-Biomedical-Inc-Announces-Second-Covid-19-Treatment-Provisional-Patent-Application-Filed-to-Supplement-Two-Issued?id=259044
Premier Biomedical, Inc. Announces Second Covid-19 Treatment Provisional Patent Application Filed to Supplement Two Issued Patents

JACKSON CENTER, PA / ACCESSWIRE / April 14, 2020 / Premier Biomedical, Inc. (OTCPINK:BIEI) announced today the filing of a provisional patent application, "Method for Treating Covid-19 Inflammatory Cytokine Storm for the Reduction of Morbidity and Mortality in Covid-19 Patients," by Mitchell S. Felder, M.D., the Chairman of the Board and Scientific Advisory Board Chairman of Premier Biomedical. Through its exclusive global patent license agreement, Premier Biomedical will have exclusive rights to practice the invention.

The provisional patent application involves the targeted removal of disease-specific antigens via an extracorporeal process. These antigens have been identified in the medical literature to be the pathophysiologic basis for the overwhelming production of lung edema and mucus in Covid-19 patients, which can kill the patient by greatly decreasing their respiratory oxygenation. By targeting these inflammatory cytokines with a complexing agent and causing them to bind together, the resulting molecular compound can then be removed in a brief clinical process.

Dr. Felder stated, "We believe that our extracorporeal approach has the potential to greatly decrease morbidity and mortality in Covid-19 patients by removing the pathophysiologic basis for ARDS (Acute Respiratory Distress Syndrome), which is the greatest threat to these patients."

William A. Hartman, President & CEO of Premier Biomedical, stated, "We are very excited to be involved in the pursuit of a cure for severely ill patients suffering from the Coronavirus pandemic. We have already received verbal agreement from our major university partner that they would be able to produce the necessary specific antibodies in a relatively short period of time. We believe that these antibodies may also be utilized as an intravenous drug therapy for Covid-19 patients in addition to their use in our extracorporeal treatment process."

Hartman continued, "The core of this technology is the selective removal of blood-borne antigens associated with the ability of Covid-19 to replicate, and is consistent with our patented core technology. This is explained in Dr. Felder's YouTube Video "A Scientific Roadmap to Cure Cancer" (

).

"Premier has repeatedly proven in the laboratory that we can remove specific selected blood-borne antigens from a similar mixture using our patented technology. This intellectual property is an expansion of our two U.S. granted patents: Sequential Extracorporeal Treatment of Bodily Fluids, US Patent No. 9,216,386, and Utilization of Stents for the treatment of Blood Borne Carcinomas, U.S. Patent No. 8,758,287. Both patents can be downloaded from the Premier Biomedical, Inc. website, www.premierbiomedical.com.

For more information please contact:
William A. Hartman
President and CEO
Premier Biomedical Inc.
[phone]
[e-mail]
http://www.premierbiomedical.com

About Premier Biomedical, Inc.

Premier Biomedical, Inc. (OTCPINK:BIEI) is a research-based publicly traded company that intends to discover and develop medical treatments for a wide range of diseases in humans. Premier has obtained, via exclusive license agreements, the technology behind three granted US Patents, multiple pending provisional patents. Founded in 2010, Premier has partnered with the University of Texas at El Paso (UTEP). In 2016, the company began developing a line of all-natural pain relief products which they began selling in early 2017 to address the rising opioid addiction problem. The company's R&D efforts are centered in El Paso, TX, and their business offices are in Western Pennsylvania. The Company is a fully-reporting issuer whose common stock trades on the OTC marketplace maintained by OTC Markets Group, Inc. under the ticker symbol "BIEI." For more information please visit our websites: http://www.premierbiomedical.com and http://www.painreliefmeds.com

Safe Harbor Notice
Certain statements contained herein are "forward-looking statements" (as defined in the Private Securities Litigation Reform Act of 1995). Premier Biomedical, Inc. cautions that statements, and assumptions made in this news release constitute forward-looking statements and makes no guarantee of future performance. Forward-looking statements are based on estimates and opinions of management at the time statements are made. These statements may address issues that involve significant risks, uncertainties, estimates made by management. Actual results could differ materially from current projections or implied results. Premier Biomedical, Inc. undertakes no obligation to revise these statements following the date of this news release.

SOURCE: Premier Biomedical, Inc.

View source version on accesswire.com:
https://www.accesswire.com/584909/Premier-Biomedical-Inc-Announces-Second-Covid-19-Treatment-Provisional-Patent-Application-Filed-to-Supplement-Two-Issued-Patents

v/r
Sterling